Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in melanoma and lung cancer models

被引：0
|
作者：
Cortellino, S. [1 ]
Quagliariello, V. [2 ]
Delfanti, G. [3 ]
Blazevits, O. [4 ]
Chiodoni, C. [5 ]
Maurea, N. [2 ]
Di Mauro, A. [6 ]
Tatangelo, F. [6 ]
Pisati, F. [7 ]
Shmahala, A. [1 ]
Lazzeri, S. [4 ]
Spagnolo, V. [1 ]
Visco, E. [4 ]
Tripodo, C. [8 ]
Casorati, G. [9 ]
Della Bona, P. [10 ]
Longo, V. [11 ]
机构：
[1] IFOM, Dept Med, IEO Campus, Milan, Italy
[2] Ist Nazl Tumori IRCCS Fdn Pascale, Div Cardiol, Naples, Italy
[3] IRCCS Osped San Raffaele, Med Oncol, Milan, Italy
[4] IFOM, Med Oncol, IEO Campus, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol, Milan, Italy
[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Pathol Unit, Naples, Italy
[7] Cogentech SB Srl, Dept Med, Milan, Italy
[8] Univ Palermo, Dept Med, Palermo, Italy
[9] IRCCS San Raffaele Sci Inst, Med Oncol, Milan, Italy
[10] IRCCS San Raffaele Sci Inst, Dept Med, Milan, Italy
[11] USC Inst Global Hlth, Gerontol Dept, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2207
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1068P
引用
收藏
页码：S644 / S644
页数：1
相关论文
共 50 条
  • [21] SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer
    Patel, Sandip P.
    Guadarrama, Elizabeth
    Chae, Young Kwang
    Dennis, Michael J.
    Powers, Benjamin C.
    Liao, Chih-Yi
    Ferri, William A.
    George, Thomas J.
    Sharon, Elad
    Ryan, Christopher W.
    Othus, Megan
    Lopez, Gabby
    Blanke, Charles D.
    Kurzrock, Razelle
    CANCER, 2024, 130 (17) : 2918 - 2927
  • [22] Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka B.
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Eastman, Lauren M.
    Maecker, Holden T.
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [23] Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
    Willsmore, Zena N.
    Coumbe, Ben G. T.
    Crescioli, Silvia
    Reci, Sara
    Gupta, Ayushi
    Harris, Robert J.
    Chenoweth, Alicia
    Chauhan, Jitesh
    Bax, Heather J.
    McCraw, Alexa
    Cheung, Anthony
    Osborn, Gabriel
    Hoffmann, Ricarda M.
    Nakamura, Mano
    Laddach, Roman
    Geh, Jenny L. C.
    MacKenzie-Ross, Alastair
    Healy, Ciaran
    Tsoka, Sophia
    Spicer, James F.
    Josephs, Debra H.
    Papa, Sophie
    Lacy, Katie E.
    Karagiannis, Sophia N.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 (03) : 544 - 556
  • [24] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
    Rogiers, Aljosja
    Dimitriou, Florentia
    Lobon, Irene
    Harvey, Catriona
    Vergara, Ismael A.
    da Silva, Ines Pires
    Lo, Serigne N.
    Scolyer, Richard A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [25] ENHANCED ANTI-TUMOR EFFECTS OF ANTI-CTLA-4 ANTIBODY AND ANTI-PD-1 ANTIBODY TO KIDNEY CANCER MODEL IN MICE
    Motoshima, Takanobu
    Komohara, Yoshihiro
    Hasita, Horlad
    Kawano, Yoshiaki
    Wada, Yoshihiro
    Takeya, Motohiro
    Eto, Masatoshi
    JOURNAL OF UROLOGY, 2014, 191 (04): : E372 - E373
  • [26] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
    Afzal, Muhammad Zubair
    Mabaera, Rodwell
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [27] Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment
    Passat, Tilda
    Touchefeu, Yann
    Gervois, Nadine
    Jarry, Anne
    Bossard, Celine
    Bennouna, Jaafar
    BULLETIN DU CANCER, 2018, 105 (11) : 1033 - 1041
  • [28] Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review
    Papouin, Barbara
    Mussini, Charlotte
    De Martin, Eleonora
    Guettier, Catherine
    ANNALES DE PATHOLOGIE, 2018, 38 (06) : 338 - 351
  • [29] Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1 checkpoint blockade
    Wei, Spencer C.
    Levine, Jacob H.
    Pe'er, Dana
    Allison, James P.
    CANCER RESEARCH, 2017, 77
  • [30] Tumor eradication in a murine model of glioma with vaccination and anti-CTLA-4 but not anti-PD-1
    Field, Cameron S.
    Hunn, Martin K.
    Ferguson, Peter M.
    Yagita, Hideo
    Hermans, Ian F.
    Ancelet, Lindsay R.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
12345